Celgene Corp. (CELG)

95.31
0.57 0.60
NASDAQ : Health Technology
Prev Close 94.74
Open 94.76
Day Low/High 94.72 / 95.44
52 Wk Low/High 58.59 / 98.97
Volume 836.48K
Avg Volume 4.16M
Exchange NASDAQ
Shares Outstanding 708.74M
Market Cap 66.13B
EPS 5.70
P/E Ratio 12.78
Div & Yield N.A. (N.A)

Takeaways and Observations

I spent most of the time in my Diary discussing banks. -- and why I am now short the sector and have placed three money centers on my Best Ideas List (short).   And I consistently noted the correlation between yields and banks...and, in turn, a mode...

Charting the Biotechs

Charting the Biotechs

Time to revisit some stocks now that biotech has cooled.

Patience Is a Virtue for Biotech Investing

Patience Is a Virtue for Biotech Investing

Valuations in some large-caps are compelling over the long term.

Takeaways and Observations

"Success breeds complacency. Complacency breeds failure. Only the paranoid survive." - Andy Grove   Perhaps this qualifies as a potential warning from "Uncle" Bob Farrell's ten lessons of investing.   Frankly, I thought dumping Ford's Fields was idi...

3 Post-Earnings Biotech Buys

3 Post-Earnings Biotech Buys

These names are now undervalued, despite solid results and good fundamentals.

3 Post-Earnings Biotech Buys

3 Post-Earnings Biotech Buys

These names are now undervalued, despite solid results and good fundamentals.

Takeaways and Observations

"She's a witch of trouble in electric blue, In her own mad mind she's in love with you. With you. Now what you gonna do? Strange brew, kill what's inside of you." -- Cream, Strange Brew     Strange brew!    You have probably forgotten October, 1987....

Added to Allergan on Weakness

Allergan , a day ahead of its earnings release, is down by over $4 on no apparent news, save a rotation out of biotech. (iShares Nasdaq Biotechnology is -3% or -$7 and we see individual equity declines in Celgene , Gilead , Acadia Pharmaceuticals , ...

Earnings: Assessing 3 Biotech Bellwethers

Earnings: Assessing 3 Biotech Bellwethers

How did Celgene, AbbVie and Gilead fare last quarter?

Celgene Has Loads of Potential

Celgene Has Loads of Potential

This stock is poised for more upside.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Early-Morning Earnings Extravaganza

It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...

Your Pinch Hitter for Today, Bret Jensen!

As always, it is good to be sitting in for Doug Kass on the Daily Diary over the next two days. There is lots to talk about. We have a flood of first-quarter earnings results that we can discuss. I will be looking to see if quarterly numbers from bi...

The Good, the Bad and the Ugly (Mid-Afternoon Edition)

"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I have to prepare for my Tulane trip. So let's move to the abbreviated Monarc...

Takeaways and Observations (Early Edition)

'Til April in Paris, chestnuts in blossom Holiday tables under the trees April in Paris, this is a feeling That no one can ever reprise - April in Paris, Vernon Duke and Yip Harburg - (rare video with Ella Fitzgerald!)  The market gapped higher and ...

Intermediate Trade: Celgene

Intermediate Trade: Celgene

I prefer a very short-term, out-of-the-money vertical call spread expiring in May.

Momentum Is Fading

Momentum Is Fading

Forget financials, stick to steady growers.

The Good, the Bad and the Ugly (EarlyAfternoon Edition)

"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I want to spend some time with my family right after the close. So let's move...

Allergan and Celgene Are in Peak Health

Allergan and Celgene Are in Peak Health

These stocks should be part of a strong first-quarter earnings season.

Takeaways And Observations

For the first time in six years the DJIA fell for the eighth consecutive day. That said the Nasdaq has risen in ten of the last thirteen trading sessions as Donald Trump may be making volatility and uncertainty great again. (For that divergence and ...

Takeaways & Observations

Risk happens fast.  Most don't short and shouldn't short -- it's a game that requires volumes of risk control.  However, I would continue to maintain well above-average cash positions.  Today was not a benign event, in my view.  Nor was it likely a ...

Celgene Has Cure for Market Blues

Celgene Has Cure for Market Blues

Strong biotech stock has surged since November and is close to all-time highs.

Cramer: The Airlines and Health-Care Names Are Really Soaring

Cramer: The Airlines and Health-Care Names Are Really Soaring

This reversal has been incredible to watch.

It's Time to Add Credit Suisse's Top 10 Stocks for 2017 to Your Portfolio

It's Time to Add Credit Suisse's Top 10 Stocks for 2017 to Your Portfolio

Research firm Credit Suisse has put together a list of 140 "top ideas" covered by their analysts.

Health Care Putting in a Base

Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...

Takeaways & Observations

This is a great invite, "Wall Street Goes to Washington," in which legendary journalist Michael Wolff will sit down with my pal, The Mooch! And it's free!  Happy eighth anniversary, Mr. Market. My Generational Low call on The Kudlow Report was the b...

Takeaways and Observations

  "Wishin' and hopin' And thinkin' and prayin'..."  -- Dusty Springfield, Wishin' and Hopin'  The gap from last week's presidential speech was filled this afternoon.  I am more negative than most and more negative than I have been in a while.  Liter...

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Go With Allergan, Celgene and 'Big Mo'

Go With Allergan, Celgene and 'Big Mo'

These two large-cap drug giants should be core parts of any well-diversified portfolio.

Takeaways and Observations

  Every single market indicator I look at is overbought.  But it's likely that shorts and underperformers are buoying stocks.  Some are at the most overbought in decades.  The bond market is clearly not as sanguine on economic growth/corporate profi...